You can buy or sell RETA and other stocks, options, ETFs, and crypto commission-free!
Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Reata Pharmaceuticals
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertensi...
Simply Wall StMar 1
When Can We Expect A Profit From Reata Pharmaceuticals, Inc. (NASDAQ:RETA)?
Reata Pharmaceuticals, Inc.’s (NASDAQ:RETA): Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company’s loss has recently broadened since it announced a -US$47.7m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$71.6m, moving ...
Seeking AlphaFeb 28
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2018 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q4 2018 Results Earnings Conference Call February 27, 2019 8:00 PM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Maury Raycroft - Jefferies Brian Skorney - Baird Charles Duncan - Cantor Matt Kaplan - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Reata Fourth Quarter and Financial Re...
Expected May 8, Pre-Market